Post Doctoral Opportunity - Discovery Sciences

Arbetsbeskrivning

Research and Development- Innovative Medicines- Discovery Sciences Imed, Molndal

Description
Hydrogen/Deuterium Exchange-Mass Spectrometry (HDX MS) studies of dynamics, ligand binding and mechanism of Phosphoinositide 3-kinases.

We are currently looking for talented scientists to join our innovative academic-style postdoc programme which spans a wide range of disciplines and aligns with one of our therapeutic areas. From our centre in Mölndal, Sweden you?ll be in a global pharmaceutical environment, working alongside our scientists who are contributing to drug discovery and development and be part of a much larger active global post doc community. You will be encouraged to pursue your own independent research in cutting edge laboratories, present at external meetings, and publish in leading journals. You will also be offered a comprehensive training programme.

You will have the support of a leading academic advisor, who?ll provide you with the guidance and knowledge you need ensure success of your projects and to help develop your career. This is an exciting opportunity, to work within a Pharmaceutical setting but maintaining a strong basic science focus aligned to drug discovery and development activities, making this an opportunity to make a real difference to the future of medical science.

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines for some of the world?s most serious diseases. At AstraZeneca, we're proud to have a unique workplace culture that inspires innovation and collaboration. Here, employees are empowered to express diverse perspectives - and are made to feel valued, energised and rewarded for their ideas and creativity.

Discovery Sciences was established in 2011 as a scientific unit that works across all disease areas, modalities, and geographic locations in supporting the identification of quality targets, hits, leads, and drug candidates. As part of our team, you will be working alongside technology experts in a truly state-of the art environment.

Studying isoform-selective inhibitors of Class I Phosphoinositide 3 Kinases (PI3K's), you will obtain a thorough understanding of disease-related enzyme mechanisms. You will be using hydrogen deuterium exchange mass spectrometry (HDX MS) to target the dynamic differences and identify isoform-specific allosteric binding sites.

Requirements:
As a Postdoctoral Scientist - Discovery Sciences using HDX MS, it's essential that you have:
- A PhD in Biochemistry, Biophysics or a related discipline
- Expertise with mass spectrometry of protein and peptides
- A genuine commitment to medical science
- Strong organisational, communication and interpersonal skills
- A proven record of work published in reputable scientific journals

The following skills and qualifications are desirable:
- A firm understanding of hydrogen deuterium exchange mass spectrometry
- Expertise with assay development
- Experience in protein expression and purification
- Knowledge of Phosphoinositide 3-kinases

As a Postdoctoral Scientist - Discovery Sciences using HDX MS, you will be:
- Working together with a highly dynamic team establishing HDX-MS as a technique to characterize binding of small molecule ligands to proteins for structure based drug design.
- Externally presenting results at scientific conferences and publishing scientific papers in high-quality peer-reviewed journals

Sammanfattning

  • Arbetsplats: AstraZeneca Mölndal
  • 1 plats
  • 6 månader eller längre
  • Heltid
  • Publicerat: 15 juli 2015

Besöksadress

PEPPAREDSLEDEN 1
MÖLNDAL

Postadress

None
MÖLNDAL, 43183

Liknande jobb


Fältassistent med inriktning på biodiversitet

Fältassistent med inriktning på biodiversitet

6 maj 2024

Field assistant  for biodiversity project

Field assistant for biodiversity project

6 maj 2024

Forskningsassistent inom Strukturell biologi av icke-kodande RNA

Forskningsassistent inom Strukturell biologi av icke-kodande RNA

3 maj 2024

Biträdande forskare

Biträdande forskare

3 maj 2024